NASDAQ:AVNR - Avanir Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Avanir Pharmaceuticals (NASDAQ:AVNR)

Avanir Pharmaceuticals logoAVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Receive AVNR News and Ratings via Email

Sign-up to receive the latest news and ratings for AVNR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:AVNR
CUSIP05348P40
Phone+1-949-3896700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Avanir Pharmaceuticals (NASDAQ:AVNR) Frequently Asked Questions

What is Avanir Pharmaceuticals' stock symbol?

Avanir Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVNR."

Has Avanir Pharmaceuticals been receiving favorable news coverage?

Media coverage about AVNR stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Avanir Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also assigned news stories about the healthcare company an impact score of 46.77 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Avanir Pharmaceuticals?

Shares of AVNR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Avanir Pharmaceuticals?

Avanir Pharmaceuticals' mailing address is 20 Enterprise Ste 200, ALISO VIEJO, CA 92656-7104, United States. The healthcare company can be reached via phone at +1-949-3896700.


MarketBeat Community Rating for Avanir Pharmaceuticals (AVNR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Avanir Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVNR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVNR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Avanir Pharmaceuticals (NASDAQ:AVNR) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/27/2016 forward)

Earnings

Avanir Pharmaceuticals (NASDAQ:AVNR) Earnings History and Estimates Chart

Earnings by Quarter for Avanir Pharmaceuticals (NASDAQ:AVNR)

Avanir Pharmaceuticals (NASDAQ AVNR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/10/2014Q4 2014($0.05)($0.08)$32.63 million$32.71 millionViewN/AView Earnings Details
8/5/2014Q314($0.08)($0.08)$29.46 million$28.60 millionViewListenView Earnings Details
5/6/2014Q214($0.08)($0.08)$28.21 million$26.95 millionViewListenView Earnings Details
2/5/2014Q114($0.08)($0.07)$24.84 million$26.70 millionViewListenView Earnings Details
12/10/2013Q4($0.07)($0.24)$21.86 million$21.70 millionViewListenView Earnings Details
8/6/2013Q3 2013($0.11)($0.08)$19.53 million$19.80 millionViewListenView Earnings Details
5/8/2013Q2 2013($0.09)($0.12)$17.40 million$17.40 millionViewListenView Earnings Details
2/7/2013Q1 2013($0.09)($0.09)$7.20 million$16.50 millionViewListenView Earnings Details
12/12/2012Q4 2012($0.08)($0.09)ViewN/AView Earnings Details
8/8/2012($0.11)($0.11)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/7/2012($0.13)($0.12)ViewN/AView Earnings Details
12/12/2011($0.16)($0.14)ViewN/AView Earnings Details
8/8/2011($0.13)($0.13)ViewN/AView Earnings Details
5/9/2011($0.14)($0.12)ViewN/AView Earnings Details
2/3/2011($0.14)($0.11)ViewN/AView Earnings Details
11/30/2010Q4 2010($0.10)($0.10)ViewN/AView Earnings Details
8/5/2010Q3 2010($0.07)($0.06)ViewN/AView Earnings Details
5/3/2010Q2 2010($0.07)($0.08)ViewN/AView Earnings Details
11/24/2009Q4 2009($0.09)ViewN/AView Earnings Details
7/29/2009Q3 2009($0.06)ViewN/AView Earnings Details
5/7/2009Q2 2009($0.06)ViewN/AView Earnings Details
2/17/2009Q1 2009($0.07)ViewN/AView Earnings Details
2/7/2009Q1 2010($0.06)ViewN/AView Earnings Details
12/15/2008Q4 2008($0.07)ViewN/AView Earnings Details
8/7/2008Q3 2008($0.02)ViewN/AView Earnings Details
5/13/2008Q2 2008($0.12)ViewN/AView Earnings Details
2/7/2008Q1 2008($0.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Avanir Pharmaceuticals (NASDAQ:AVNR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Avanir Pharmaceuticals (NASDAQ AVNR) Insider Trading and Institutional Ownership History

Insider Trading History for Avanir Pharmaceuticals (NASDAQ:AVNR)

Avanir Pharmaceuticals (NASDAQ AVNR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2014Christine OcampoVPSell35,780$16.94$606,113.20View SEC Filing  
12/18/2014Joao Md SiffertSVPSell15,505$16.93$262,499.65View SEC Filing  
12/17/2014Keith KatkinCEOSell277,680$16.95$4,706,676.00View SEC Filing  
11/28/2014Rohan PalekarSVPSell15,000$15.00$225,000.00View SEC Filing  
10/24/2014Christine OcampoVPSell2,080$11.81$24,564.80View SEC Filing  
10/24/2014Joao Md SiffertSVPSell8,426$11.80$99,426.80View SEC Filing  
10/24/2014Keith KatkinCEOSell27,567$11.76$324,187.92View SEC Filing  
9/15/2014Christine OcampoVPSell55,000$9.45$519,750.00View SEC Filing  
9/15/2014Rohan PalekarSVPSell25,000$11.50$287,500.00View SEC Filing  
8/1/2014Keith KatkinCEOSell9,670$5.26$50,864.20View SEC Filing  
5/16/2014Christine OcampoVPSell37,496$5.05$189,354.8081,981View SEC Filing  
12/17/2013Rohan PalekarSVPBuy10,000$2.80$28,000.00143,000View SEC Filing  
11/4/2013Rohan PalekarSVPBuy10,000$4.19$41,900.00View SEC Filing  
9/18/2013Joao Md SiffertSVPSell21,094$4.22$89,016.68116,200View SEC Filing  
8/2/2013Keith KatkinCEOSell15,500$4.84$75,020.00View SEC Filing  
5/15/2013Christine OcampoVPSell77,700$3.29$255,633.00View SEC Filing  
5/15/2013Keith KatkinCEOSell250,438$3.26$816,427.88View SEC Filing  
12/13/2012Rohan PalekarSVPBuy10,000$2.46$24,600.00View SEC Filing  
12/3/2012Christine OcampoVPSell2,845$2.55$7,254.75View SEC Filing  
12/3/2012Keith KatkinCEOSell18,250$2.55$46,537.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Avanir Pharmaceuticals (NASDAQ AVNR) News Headlines

Source:
DateHeadline
Reviewing Teva Pharmaceutical Industries (TEVA) & Avanir Pharmaceuticals (AVNR)Reviewing Teva Pharmaceutical Industries (TEVA) & Avanir Pharmaceuticals (AVNR)
www.americanbankingnews.com - March 17 at 7:08 PM
Analyzing Theravance Biopharma (TBPH) & Avanir Pharmaceuticals (AVNR)Analyzing Theravance Biopharma (TBPH) & Avanir Pharmaceuticals (AVNR)
www.americanbankingnews.com - October 16 at 8:30 PM
Avanir Pharmaceuticals Appoints Richard Malamut, MD, as Senior Vice President, Research & Development, and Chief Medical OfficerAvanir Pharmaceuticals Appoints Richard Malamut, MD, as Senior Vice President, Research & Development, and Chief Medical Officer
finance.yahoo.com - October 5 at 2:14 PM
Report: KC-area docs who were paid the most by drug, device companiesReport: KC-area docs who were paid the most by drug, device companies
finance.yahoo.com - July 5 at 4:51 PM
Avanir Pharma (AVNR) Launches ONZETRA Xsail in the US - StreetInsider.comAvanir Pharma (AVNR) Launches ONZETRA Xsail in the US - StreetInsider.com
www.streetinsider.com - May 16 at 1:45 PM
MC10, Inc. Appoints Eric K. Brandt to its Board of Directors - Business Wire (press release)MC10, Inc. Appoints Eric K. Brandt to its Board of Directors - Business Wire (press release)
www.businesswire.com - April 1 at 9:49 PM
Avanir Pharma (AVNR) Reports FDA Approval of ONZETRA to Treat Migraine - StreetInsider.comAvanir Pharma (AVNR) Reports FDA Approval of ONZETRA to Treat Migraine - StreetInsider.com
www.streetinsider.com - January 29 at 10:10 AM
Acquisition of Avanir Pharmaceuticals, Inc. (AVNR) by Otsuka Pharmaceutical Co., Ltd. May Not Be in Shareholders Best InterestsAcquisition of Avanir Pharmaceuticals, Inc. (AVNR) by Otsuka Pharmaceutical Co., Ltd. May Not Be in Shareholders' Best Interests
www.prnewswire.com - January 23 at 9:36 AM
Avanir Pharma Names Rohan Palekar As President And CEO, Succeeding KatkinAvanir Pharma Names Rohan Palekar As President And CEO, Succeeding Katkin
www.nasdaq.com - January 21 at 4:54 PM
Avanir Pharma Names Rohan Palekar As President And CEO, Succeeding Katkin - RTT NewsAvanir Pharma Names Rohan Palekar As President And CEO, Succeeding Katkin - RTT News
www.rttnews.com - January 20 at 9:43 AM
Avanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 BillionAvanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion
www.prnewswire.com - January 16 at 6:06 PM
Japanese firm Otsuka to buy Avanir Pharmaceuticals for $3.5 billionJapanese firm Otsuka to buy Avanir Pharmaceuticals for $3.5 billion
www.latimes.com - December 2 at 8:39 PM

SEC Filings

Avanir Pharmaceuticals (NASDAQ:AVNR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Avanir Pharmaceuticals (NASDAQ:AVNR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Avanir Pharmaceuticals (NASDAQ AVNR) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.